Total Payments
$138,323
2024 Payments
$56,760
Companies
52
Transactions
359
Medicare Patients
1,303
Medicare Billing
$103,025
Payment Breakdown by Category
Research$85,193 (61.6%)
Other$38,816 (28.1%)
Food & Beverage$7,531 (5.4%)
Travel$6,000 (4.3%)
Consulting$600.00 (0.4%)
Education$182.96 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $85,193 | 11 | 61.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $38,816 | 20 | 28.1% |
| Food and Beverage | $7,531 | 278 | 5.4% |
| Travel and Lodging | $6,000 | 36 | 4.3% |
| Consulting Fee | $600.00 | 2 | 0.4% |
| Education | $182.96 | 12 | 0.1% |
Payments by Type
Research
$85,193
11 transactions
General
$53,130
348 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $83,550 | 10 | $0 (2024) |
| ABBVIE INC. | $30,898 | 116 | $0 (2024) |
| Astellas Pharma US Inc | $13,346 | 21 | $0 (2024) |
| Eli Lilly and Company | $1,643 | 1 | $0 (2024) |
| Alnylam Pharmaceuticals Inc. | $1,398 | 9 | $0 (2024) |
| Duchesnay USA Incorporated | $1,300 | 11 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $1,124 | 7 | $0 (2017) |
| AMAG Pharmaceuticals, Inc. | $787.79 | 13 | $0 (2019) |
| Aspira Women's Health Inc | $600.00 | 2 | $0 (2020) |
| Sumitomo Pharma America, Inc. | $345.38 | 18 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $56,760 | 47 | Teva Pharmaceuticals USA, Inc. ($52,560) |
| 2023 | $44,598 | 59 | Teva Pharmaceuticals USA, Inc. ($30,990) |
| 2022 | $6,368 | 39 | ABBVIE INC. ($5,778) |
| 2021 | $5,925 | 38 | AbbVie Inc. ($5,636) |
| 2020 | $4,213 | 24 | AbbVie Inc. ($3,414) |
| 2019 | $8,105 | 47 | AbbVie, Inc. ($7,642) |
| 2018 | $8,704 | 51 | AbbVie, Inc. ($8,098) |
| 2017 | $3,650 | 54 | Duchesnay USA Incorporated ($1,280) |
All Payment Transactions
359 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | MAYNE PHARMA COMMERCIAL LLC | — | Food and Beverage | In-kind items and services | $17.98 | General |
| 12/12/2024 | Sumitomo Pharma America, Inc. | MYFEMBREE (Drug) | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: HORMONE THERAPY | ||||||
| 12/03/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $28.53 | General |
| Category: Biological | ||||||
| 11/19/2024 | PFIZER INC. | ABRYSVO (Biological) | Food and Beverage | In-kind items and services | $17.02 | General |
| Category: VACCINES | ||||||
| 11/14/2024 | Sumitomo Pharma America, Inc. | MYFEMBREE (Drug) | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: HORMONE THERAPY | ||||||
| 11/12/2024 | Astellas Pharma US Inc | Veozah (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $515.00 | General |
| Category: Biological | ||||||
| 11/06/2024 | Bayer Healthcare Pharmaceuticals Inc. | Mirena (Drug), Kyleena | Food and Beverage | In-kind items and services | $34.14 | General |
| Category: Womens Health | ||||||
| 11/02/2024 | MAYNE PHARMA COMMERCIAL LLC | — | Food and Beverage | In-kind items and services | $13.64 | General |
| 10/31/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $24.99 | General |
| Category: Biological | ||||||
| 10/25/2024 | Sumitomo Pharma America, Inc. | MYFEMBREE (Drug) | Food and Beverage | In-kind items and services | $12.82 | General |
| Category: HORMONE THERAPY | ||||||
| 10/17/2024 | Exeltis, USA Inc. | SLYND (Drug) | Food and Beverage | In-kind items and services | $23.54 | General |
| Category: CONTRACEPTIVE | ||||||
| 10/07/2024 | Sumitomo Pharma America, Inc. | MYFEMBREE (Drug) | Food and Beverage | In-kind items and services | $27.22 | General |
| Category: HORMONE THERAPY | ||||||
| 09/30/2024 | Eli Lilly and Company | — | — | In-kind items and services | $1,642.82 | Research |
| Study: A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BIMAGRUMAB AND TIRZEPATIDE, ALONE OR IN COMBINATION, TO INVESTIGATE THE EFFICACY AND SAFETY IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITHOUT TYPE 2 DIABETES | ||||||
| 09/29/2024 | MAYNE PHARMA COMMERCIAL LLC | — | Food and Beverage | In-kind items and services | $8.69 | General |
| 09/18/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $33.06 | General |
| Category: Oncology | ||||||
| 09/16/2024 | ABBVIE INC. | NATRELLE SALINE-FILLED BREAST IMPLANTS (Device) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: PLASTIC SURGERY | ||||||
| 09/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $37.10 | General |
| 09/13/2024 | Astellas Pharma Global Development | Veozah (Drug) | Food and Beverage | In-kind items and services | $21.28 | General |
| Category: Biological | ||||||
| 08/08/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $397.09 | General |
| 08/08/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $348.20 | General |
| 08/08/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $237.63 | General |
| 08/08/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $164.94 | General |
| 08/08/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $81.46 | General |
| 08/08/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $51.46 | General |
| 08/08/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $47.72 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Inserts 4 mcg (Teva Pharmaceuticals, Inc.) With IMVEXXY (Estradiol Vaginal Inserts) (TherapeuticsMD, Inc.) in the Treatment of Dyspareunia in Women With Vulvar and Vaginal Atrophy | Teva Pharmaceuticals USA, Inc. | $83,550 | 10 |
| A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BIMAGRUMAB AND TIRZEPATIDE, ALONE OR IN COMBINATION, TO INVESTIGATE THE EFFICACY AND SAFETY IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITHOUT TYPE 2 DIABETES | Eli Lilly and Company | $1,643 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 393 | 433 | $117,379 | $28,782 |
| 2022 | 10 | 393 | 437 | $123,809 | $32,349 |
| 2021 | 7 | 297 | 344 | $96,236 | $26,250 |
| 2020 | 10 | 220 | 264 | $63,881 | $15,644 |
Total Patients
1,303
Total Services
1,478
Medicare Billing
$103,025
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 77067 | Screening mammography | Office | 2023 | 61 | 61 | $36,600 | $7,876 | 21.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 59 | 92 | $23,368 | $6,112 | 26.2% |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | Office | 2023 | 82 | 82 | $11,025 | $3,340 | 30.3% |
| 77063 | Screening 3d breast mammography | Office | 2023 | 62 | 62 | $11,880 | $3,318 | 27.9% |
| 76830 | Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | Office | 2023 | 21 | 28 | $11,872 | $2,545 | 21.4% |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | Office | 2023 | 40 | 40 | $6,206 | $1,734 | 27.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 19 | 19 | $7,258 | $1,658 | 22.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 11 | 11 | $4,158 | $1,140 | 27.4% |
| 58100 | Biopsy of lining of uterus | Office | 2023 | 12 | 12 | $4,596 | $946.54 | 20.6% |
| 82270 | Stool analysis for blood to screen for colon tumors | Office | 2023 | 26 | 26 | $416.00 | $111.54 | 26.8% |
| 77067 | Screening mammography | Office | 2022 | 63 | 63 | $37,800 | $8,359 | 22.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 77 | 115 | $29,210 | $7,476 | 25.6% |
| 77063 | Screening 3d breast mammography | Office | 2022 | 66 | 66 | $7,920 | $3,604 | 45.5% |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | Office | 2022 | 65 | 65 | $7,800 | $2,738 | 35.1% |
| 76830 | Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | Office | 2022 | 22 | 26 | $11,024 | $2,323 | 21.1% |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | Office | 2022 | 44 | 44 | $5,280 | $1,968 | 37.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 13 | 13 | $7,566 | $1,819 | 24.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 17 | 18 | $6,804 | $1,796 | 26.4% |
| 58100 | Biopsy of lining of uterus | Office | 2022 | 12 | 13 | $5,057 | $1,142 | 22.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 14 | 14 | $5,348 | $1,124 | 21.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 63 | 98 | $24,892 | $6,890 | 27.7% |
| 77067 | Screening mammography of both breasts | Office | 2021 | 49 | 49 | $29,400 | $6,661 | 22.7% |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | Office | 2021 | 82 | 82 | $9,840 | $3,411 | 34.7% |
| 77063 | Screening digital tomography of both breasts | Office | 2021 | 49 | 49 | $5,880 | $2,779 | 47.3% |
| 76830 | Ultrasound pelvis through vagina | Office | 2021 | 19 | 26 | $11,024 | $2,675 | 24.3% |
About Dr. Samuel Lederman, M.D
Dr. Samuel Lederman, M.D is a Obstetrics & Gynecology healthcare provider based in Lake Worth, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124131230.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Samuel Lederman, M.D has received a total of $138,323 in payments from pharmaceutical and medical device companies, with $56,760 received in 2024. These payments were reported across 359 transactions from 52 companies. The most common payment nature is "" ($85,193).
As a Medicare-enrolled provider, Lederman has provided services to 1,303 Medicare beneficiaries, totaling 1,478 services with total Medicare billing of $103,025. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Obstetrics & Gynecology
- Location Lake Worth, FL
- Active Since 08/16/2006
- Last Updated 06/22/2023
- Taxonomy Code 207V00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1124131230
Products in Payments
- ESTRADIOL (Drug) $83,550
- Veozah (Drug) $13,281
- ORIAHNN (Drug) $12,763
- Orilissa (Drug) $10,994
- Lupron (Drug) $4,863
- ORILISSA (Drug) $1,712
- Diclegis (Drug) $1,270
- ENTRESTO (Drug) $1,124
- INTRAROSA (Drug) $780.00
- OVA1 (Device) $600.00
- MYFEMBREE (Drug) $486.17
- LO LOESTRIN FE (Drug) $314.73
- SONATA SONOGRAPHY-GUIDED TRANSCERVICAL FIBROID ABLATION SYSTEM (Device) $233.20
- Kyleena (Drug) $196.44
- XEOMIN (Biological) $170.50
- MYRISK (Device) $155.15
- PREMARIN (Drug) $128.86
- ANNOVERA (Drug) $116.57
- Uterine Manipulators & Injectors (Device) $101.10
- LILETTA (Drug) $87.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Obstetrics & Gynecology Doctors in Lake Worth
Gloria Hakkarainen, M.d, M.D
Obstetrics & Gynecology — Payments: $7,723
Obstetrics & Gynecology $7,723
Sylvia Siegfried, M.d, M.D
Obstetrics & Gynecology — Payments: $4,164
Obstetrics & Gynecology $4,164
Ms. Joy Cavalaris, M.d, M.D
Obstetrics & Gynecology — Payments: $3,740
Obstetrics & Gynecology $3,740
Dr. Sameh Wanis, D.o, D.O
Obstetrics & Gynecology — Payments: $842.91
Obstetrics & Gynecology $842.91
Dr. Ana Ferwerda, M.d, M.D
Obstetrics & Gynecology — Payments: $139.61
Obstetrics & Gynecology $139.61
Marlynn Nunez, Md, MD
Obstetrics & Gynecology — Payments: $83.82
Obstetrics & Gynecology $83.82